Psoriasis is a common, chronic, systemic, inflammatory disease of the skin that is often associated with inflammatory musculoskeletal disease. Psoriasis impacts on affected individuals and on society at many levels, being associated with considerable economic burden and impaired quality of life. This article aims to provide dermatologists and their allied healthcare professionals, particularly those practicing in Africa and the Middle East, with a review of the current understanding of psoriasis, its treatment and impact, as a backdrop for further discussion of the management of psoriasis in these regions. Insight into the real-life, day-to-day challenges and unmet needs currently facing dermatologists in Africa and the Middle East is provided by the authors, most of whom are experienced dermatologists practicing in this region.
GreavesMWWeinsteinGD: Treatment of psoriasis. N Engl J Med1995; 332: 581–588.
2.
LoffredoSAyalaFMaroneG: Immunopathogenesis of psoriasis and pharmacological perspectives. J Rheumatol Suppl2009; 83: 9–11.
3.
KimballABJacobsonCWeissS: The psychosocial burden of psoriasis. Am J Clin Dermatol2005; 6: 383–392.
4.
KurdSKGelfandJM: The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from the NHANES 2003–2004. J Am Acad Dermatol2009; 60: 218–224.
5.
MrowietzUKragballeKReichK: Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res2011; 303: 1–10.
6.
ShellehHHAl-HatitiHS: Pattern of skin diseases in a hospital in southwestern Saudi Arabia. Saudi Med J2004; 25: 507–510.
7.
AlaklobyOM: Pattern of skin disease in eastern Saudi Arabia. Saudi Med J2005; 26: 1607–1610.
8.
HartshorneST: Dermatological disorders in Johannesburg, South Africa. Clin Exp Dermatol2003; 28: 661–665.
9.
GelfandJMWeinsteinRPorterSB: Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol2005; 141: 1537–1541.
10.
ChristophersE: Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol2001; 26: 314–320.
11.
NeimannALPorterSBGelfandJM: The epidemiology of psoriasis. Expert Rev Dermatol2006; 1: 63–75.
12.
AugustinMReichKGlaeskeG: Comorbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol2010; 90: 147–151.
13.
Al-MutairiNAl-FaragSAl MutairiA: Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol2010; 37: 146–155.
14.
MrowietzUElderJTBarkerJ: The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res2006; 298: 309–319.
15.
MorrisARogersMFischerG: Childhood psoriasis: A clinical review of 1262 cases. Pediatr Dermatol2001; 18: 188–198.
16.
Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A, Capon F, et al: A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet2010; 42: 985–990.
17.
Di CesareADi MeglioPNestleFO: The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol2009; 129: 1339–1350.
18.
KurzejaMRudnickaLOlszewskaM: New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol2011; 12: 113–125.
19.
LederROFarberEM: The variable incidence of psoriasis in sub-Saharan Africa. Int J Dermatol1997; 36: 911–919.
20.
GuinotCLatreilleJPerrusselM: Psoriasis: characterization of six different clinical phenotypes. Exp Dermatol2009; 18: 712–719.
21.
MacDonaldABurdenAD: Psoriasis: advances in pathophysiology and management. Postgrad Med J2007; 83: 690–697.
LangleyRGKruegerGGGriffithsCE: Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis2005; 64 (suppl 2): ii18–ii25.
24.
SchmittJWozelG: The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology2005; 210: 194–199.
25.
RamsayBLawrenceCM: Measurement of involved surface area in patients with psoriasis. Br J Dermatol1991; 124: 565–570.
26.
Tiling-GrosseSReesJ: Assessment of area of involvement in skin disease: A study using schematic figure outlines. Br J Dermatol1993; 128: 69–74.
27.
Berth-JonesJGrotzingerKRainvilleC: A study examining inter- and intrarater reliability of the three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol2006; 155: 707–713.
28.
LangleyRGEllisCN: Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol2004; 51: 563–569.
29.
PuzenatEBronsardVPreyS: What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol2010; 24 (suppl 2): 10–16.
30.
Schmid-OttGSchallmayerSCalliessIT: Quality of life in patients with psoriasis and psoriatic arthritis with a special focus on stigmatization. Clin Dermatol2007; 25: 547–554.
31.
Al-MazeediKEl-ShazlyMAl-AjmiHS: Impact of psoriasis on quality of life in Kuwait. Int J Dermatol2006; 45: 418–424.
32.
AghaeiSMoradiAArdekaniGS: Impact of psoriasis on quality of life in Iran. Indian J Dermatol Venereol Leprol2009; 75: 220–224.
33.
ZghalAZeglaouiFKallelL: Quality of life in dermatology: Tunisian version of the Skindex-29. Tunis Med2003; 81: 34–37 [in French, English abstract].
34.
SchäferIHackerJRustenbachSJ: Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol2010; 20: 62–67.
35.
HeydendaelVMde DorgieCASpulsPI: The burden of psoriasis is not determined by disease severity only. J Invest Dermatol Symp Proc2004; 9: 131–135.
36.
MeasePJMenterMA: Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol2006; 54: 685–704.
37.
FinlayAYKhanGK: Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol1994; 19: 210–216.
38.
BasraMKFenechRGattRM: The Dermatology Life Quality Index 1994–2007: A comprehensive review of validation data and clinical results. Br J Dermatol2008; 159: 997–1035.
39.
SampognaFTabolliSSöderfeldtB: Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol2006; 154: 844–849.
40.
Scottish Intercollegiate Guidelines Network (SIGN): Diagnosis and Management of Psoriasis and Psoriatic Arthritis in Adults. SIGN Publication No. 121, Edinburgh: SIGN, 2010 (available at http://www.sign.ac.uk).
41.
AyalaFAyalaF: Clinical aspects and comorbidities of psoriasis. J Rheumatol Suppl2009; 83: 19–20.
42.
LudwigRJRostockAOchsendorfFR: Psoriasis: A possible risk factor for development of coronary artery calcification. Br J Dermatol2007; 156: 271–276.
43.
MenterAGriffithsCETebbeyPW: Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol2010; 24: 1371–1377.
44.
MebazaaAEl AsmiMZidiW: Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. J Eur Acad Dermatol Venereol2010; 25: 705–709.
AzfarRSGelfandJM: Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol2008; 20: 416–422.
48.
LoveTJQureshiAAKarlsonEW: Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol2011; 147: 419–424.
49.
NeimannALShinDBWangX: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol2006; 55: 829–855.
50.
BoehnckeW-HBoehnckeSSchönMP: Managing comorbid disease in patients with psoriasis. BMJ2010; 340: b5666 (doi: 10.1136/bmj.b5666).
51.
KimballABGladmanDGelfandJM: National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol2008; 58: 1031–1042.
52.
MeasePJ: Psoriatic arthritis. Update on pathophysiology, assessment, and management. Bull N Y U Hosp Jt Dis2010; 68: 191–198.
53.
LeeSMendelsohnASarnesE: The burden of psoriatic arthritis: A literature review from a global health systems perspective. P T2010; 35: 680–689.
54.
GelfandJMGladmanDDMeasePJ: Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol2005; 53: 573–577.
55.
TaylorWJ: Epidemiology of psoriatic arthritis. Curr Opin Rheumatol2002; 14: 98–103.
56.
CioconDHHornEJKimballAB: Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only: results of the 2005 Spring US National Psoriasis Foundation Survey. Am J Clin Dermatol2008; 9: 111–117.
57.
ChristophersEBarkerJNGriffithsCE: The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol2010; 24: 548–554.
58.
PreySPaulCBronsardV: Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: A systematic review of the literature. J Eur Acad Dermatol Venereol2010; 24 (suppl 2): 31–35.
59.
IbrahimGWaxmanRHelliwellPS: The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum2009; 61: 1373–1378.
60.
ZachariaeHZachariaeRBlomqvistK: Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol2002; 82: 108–113.
61.
MeasePJAntoniCEGladmanDD: Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis2005; 64 (suppl 2): ii49–ii54.
62.
KavanaughACassellS: The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol2005; 23 (5 suppl 39): S142–S147.
63.
MeasePJ: Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis2002; 61: 298–304.
64.
HüffmeierUUebeSEkiciAB: Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet2010; 42: 996–999.
65.
VealeDJRitchlinCFitzGeraldO: Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis2005; 64 (suppl 2): ii26–ii29.
66.
TaylorWGladmanDHelliwellP: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum2006; 54: 2665–2673.
67.
BurdenADBoonM HiltonLemanJ: Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance. BMJ2010; 341: c5623 (doi: 10.1136/bmj.c5623).
68.
WilsonFCIcenMCrowsonCS: Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. Arthritis Rheum2009; 61: 233–239.
69.
De SimoneCCaldarolaGAgostinoM D: Usefulness of ultrasound imaging in detecting psoriatic arthritis of fingers and toes in patients with psoriasis. Clin Dev Immunol2011; 2011: 390726 [epub ahead of print].
70.
DominguezPGladmanDDHelliwellP: Development of screening tools to identify psoriatic arthritis. Curr Rheumatol Rep2010; 12: 295–299.
71.
TaylorSLPetrieMO'RourkeKS: Rheumatologists’ recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients’ joint symptoms. J Dermatol Treat2009; 20: 350–353.
72.
ChandranVGottliebACookRJ: International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum2009; 61: 1235–1342.
73.
GargAGladmanD: Recognizing psoriatic arthritis in the dermatology clinic. J Am Acad Dermatol2010; 63: 733–748.
74.
SorianoERMcHughNJ: Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol2006; 33: 1422–1430.
75.
WarrenRBBrownBCGrindlayDJ: What's new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009. Clin Exp Dermatol2010; 35: 688–691.
76.
TanJKWolfeBJBulatovicR: Critical appraisal of quality of clinical practice guidelines for treatment of psoriasis vulgaris, 2006–2009. J Invest Dermatol2010; 130: 2389–2395.
77.
NastASpulsPHOrmerodAD: A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: ‘AGREE-ing’ on a common base for European evidence-based psoriasis treatment guidelines. J Eur Acad Dermatol Venereol2009; 23: 782–787.
78.
RaboobeeNAboobakerJJordaanHF: Guideline on the management of psoriasis in South Africa. S Afr Med J2010; 100: 255–282.
79.
KurianABarankinB: Current effective topical therapies in the management of psoriasis. Skin Therapy Lett2011; 16: 4–7.
80.
MenterAGottliebAFeldmanSR: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol2008; 58: 826–850.
81.
MenterAKormanNJElmetsCA: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol2009; 60: 643–659.
82.
MenterAKormanNJElmetsCA: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol2010; 62: 114–135.
83.
MenterAKormanNJElmetsCA: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol2009; 61: 451–485.
84.
SmithCHAnsteyAVBarkerJN: British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol2009; 161: 987–1019.
85.
NastAAugustinMBoehnckeWH: Evidence-based (S3) guideline for the treatment of psoriasis vulgaris—Update: “Therapeutic options” and “Efalizumab”. J Dtsch Dermatol Ges2010; 8: 65–66 [in English and German].
86.
National Institute for Health and Clinical Excellence (NICE): Infliximab for the Treatment of Adults with Psoriasis. London: NICE, January 2008 (available at: http://guidance.nice.org.uk/TA134).
87.
National Institute for Health and Clinical Excellence (NICE): Etanercept and Efalizumab for the Treatment of Adults with Psoriasis. London: NICE, July 2006 (available at: http://guidance.nice.org.uk/TA103).
88.
National Institute for Health and Clinical Excellence (NICE): Adalimumab for the Treatment of Adults with Psoriasis. London: NICE, June 2008 (available at: http://guidance.nice.org.uk/TA146).
89.
National Institute for Health and Clinical Excellence (NICE): Ustekinumab for the Treatment of Adults with Moderate to Severe Psoriasis. London: NICE, September 2009 (available at: http://guidance.nice.org.uk/TA180).
90.
PappKAPoulinYBissonnetteR: Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol2010; [epub ahead of print].
91.
van LümigPDriessenRBerendsM: Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol2011 (doi: 10.1111/j.1468–3083.2011.04044.x) [Epub ahead of print].
92.
DriessenRJBoezemanJBvan de KerkhofPC: Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol2009; 160: 670–675.
93.
Schmitt-EgenolfM: PsoReg—the Swedish registry for systemic psoriasis treatment. The registry's design and objectives. Dermatology2007; 214: 112–117.
94.
LecluseLLNaldiLSternRS: National registries of systemic treatment for psoriasis and the European ‘Psonet’ initiative. Dermatology2009; 218: 347–356.
95.
BoehnckeSSalgoRGarbaravicieneJ: Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol2011; 25: 1187–1193.
96.
HürlimannDForsterANollG: Antitumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation2002; 106: 2184–2187.
97.
IraceCMancusoGFiaschiE: Effect of anti TNFα therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis2004; 177: 113–118.
98.
JacobssonLTTuressonCGülfeA: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol2005; 32: 1213–1218.
99.
DixonWGWatsonKDLuntM: Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum2007; 56: 2905–2912.
100.
NastAReytanNRosumeckS: Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol2008; 22: 1337–1342.
101.
KnightCMauskopfJEkelundM: Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Health Econ2011; [epub ahead of print].
102.
Heinen-KammererTDanielDStratmannL: Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges2007; 5: 762–768 [in English and German].
103.
NelsonAAPearceDJFleischerABJr: Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol2008; 58: 125–135.
104.
RavalKLoflandJHWatersH: Disease and treatment burden of psoriasis: examining the impact of biologics. J Drug Dermatol2011; 10: 189–196.
105.
SatoRMilliganGMoltaC: Health-related quality of life and healthcare resource use in European patients with plaque psoriasis: an association independent of observed disease severity. Clin Exp Dermatol2011; 36: 24–28.
106.
TorresRASilvaSAMagalhãesRF: Comparison of quality of life questionnaires and their correlation with the clinical course of patients with psoriasis. An Bras Dermatol2011; 86: 45–49 [in English and Portuguese].
107.
LeeYWParkEJKwonIH: Impact of psoriasis on quality of life: relationship between clinical response to therapy and change in health-related quality of life. Ann Dermatol2010; 22: 389–396.
